Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital by Schee, C. (Cindy) van der et al.
Research
Emerging Infectious Diseases 862 Vol. 7, No. 5, September-October 2001
Rapid Emergence of Ciprofloxacin-Resistant 
Enterobacteriaceae Containing Multiple 
Gentamicin Resistance-Associated Integrons 
in a Dutch Hospital
Alex van Belkum, Wil Goessens, Cindy van der Schee, Nicole Lemmens-den Toom, 
Margreet C. Vos, Jan Cornelissen, Elly Lugtenburg, Siem de Marie, 
Henri Verbrugh, Bob Löwenberg, and Hubert Endtz 
Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
In a hematology unit in the Netherlands, the incidence of ciprofloxacin-resis-
tant Enterobacter cloacae and Escherichia coli increased from <0.5% to
20.7% and <0.5% to 64%, respectively, from 1996 to 1999. Clonal spread of
single genotypes of both ciprofloxacin-resistant E. coli and Enterobacter clo-
acae from patient to patient was documented by pulsed-field gel electro-
phoresis and random amplification of polymorphic DNA. In addition,
genetically heterogeneous strains were isolated regularly. Integrons associ-
ated with gentamicin resistance were detected in Enterobacter cloacae and
E. coli strains. Integron-containing E. coli were detected in all hematology
wards. In contrast, in Enterobacter cloacae strains two integron types were
encountered only in the isolates from one ward. Although in all patients
identical antibiotic regimens were used for selective decontamination, we
documented clear differences with respect to the nosocomial emergence of
ciprofloxacin-resistant bacterial strains and gentamicin resistance-associ-
ated integrons.
Patients with severe neutropenia (neutrophil count
<500/µL) are at risk for bacterial and fungal infections. In
addition to exogenous routes of infection, the endogenous
intestinal bacterial flora is a potential source of life-threat-
ening bacteremia caused by gram-negative microorganisms.
Patients are especially vulnerable who have prolonged peri-
ods of neutropenia (>10 days), a very low neutrophil count
(<100/µL), and mucositis due to anticancer chemotherapy. To
reduce the incidence of bacteremia, such patients often
receive antibiotic prophylaxis, called selective decontamina-
tion of the gut. This prophylaxis is intended to eliminate
potentially pathogenic bacterial species while maintaining
native anaerobic flora. The fluoroquinolones (e.g., ciprofloxa-
cin) appear to combine excellent activity, good bioavailability,
and high concentrations in the gut, and thus provide an
important component of the standard selective decontamina-
tion in many centers (1). Successful implementation of this
method has been reported for liver transplant patients (2),
patients with cirrhosis and acute upper gastrointestinal
hemorrhage (3), and hematooncology patients (4,5). How-
ever, a drawback is that the use of broad-spectrum antibiot-
ics may eventually lead to selection of antimicrobial
resistance (6-8), especially when patients have received prior
courses of antibiotic treatment (9). Concern about emergence
of multidrug-resistant microorganisms is one of the main
reasons that decontamination procedures have not been gen-
erally accepted.
Bacteria such as Escherichia coli and Enterobacter cloa-
cae exist in the human gut, as well as the environment.
These bacteria represent an important class of opportunistic
pathogenic microorganisms. The number of strains that are
resistant, especially to antibiotics that are frequently used
for selective decontamination, is increasing. In the United
States, Canada, Latin America, Sicily, Spain, and Kuwait,
for example, ciprofloxacin is no longer the most effective
drug for treating bloodstream infections caused by gram-
negative bacilli (9-12). Recent French and Belgian studies
presented detailed, nationwide analyses of the emergence of
antibiotic-resistant strains of Enterobacter aerogenes and
associated risk factors (13-15). The emergence of nosocomi-
ally disseminating clones can be explained by the fact that
ciprofloxacin resistance is due to point mutations in DNA
gyrase and topoisomerase genes. The latter genes are not
known to be interchangeable or prone to recombination
among resistant and susceptible enterobacterial isolates.
Most bacterial strains derived from bloodstream infections
acquired in northern European countries were still highly
susceptible to ciprofloxacin (16,17). An additional, complicat-
ing factor is that antibiotic-resistance genes are frequently
trapped in cassettes, the so-called integrons (18-20), which
provide an efficient means for capturing and exchanging
resistance genes. This implies that both bacterial strain
characteristics and the exchange and dissemination of resis-
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tance genes need to be considered during ongoing outbreaks
of infection (21).
Our molecular epidemiologic study was undertaken as
part of an effort to understand the rapid spread of ciprofloxa-
cin-resistant enterobacteriaceae in a hematooncology depart-
ment. Subsequent microbiologic analysis of the E. coli and E.
cloacae strains involved revealed a high prevalence of inte-
gron-associated gentamicin resistance as well. In addition to
whole genome typing of the bacterial isolates, integron poly-
morphism was assessed with the help of a polymerase chain
reaction restriction fragment-length polymorphism (PCR-
RFLP) assay. The study environment comprised three clini-
cal wards of one department of hematology, housed in two
buildings: one at the south bank of Rotterdam harbor, con-
taining two hematology wards where patients are treated for
hematologic malignancies, and the other at the north bank,
containing one similar ward. The prevalence of several anti-
microbial resistance traits was assessed, isolates were char-
acterized by pulsed-field gel electrophoresis (PFGE) or
random amplification of polymorphic DNA (RAPD) analysis,
and the presence and variability of integrons were deter-
mined.
Materials and Methods
Patients
All isolates were cultured from patients admitted to one
of the three hematology wards (Table 1). Units A and B were
located in the same building. Units B and C consisted of sin-
gle-person rooms with anterooms and private bathrooms,
negative air flow, and HEPA-filtered air supply. Gloves and
gowns were worn by staff on all occasions. To prevent possi-
ble food-related infections, all foods were specifically
selected: items likely to be contaminated with large numbers
of bacteria (uncooked vegetable such as lettuce, fermented
cheese, and several fruit species) were avoided. Unit A was
made up of shared rooms only (up to four patients per room).
All patients received the same selective decontamination
procedure, which was started on the day of admission. The
standard regimen involved ciprofloxacin (2 doses a day,
either 500 mg orally or 400 mg intravenously). If ciprofloxa-
cin-resistant gram-negative bacilli were present in surveil-
lance cultures, patients received 4 doses a day of 200 mg
colistin plus 5 mL of a 1 mg/mL colistin-containing solution,
combined with 3 doses a day of 1 mL of 80 mg/mL tobramy-
cin. Surveillance cultures were taken weekly from nose,
throat, urine, vagina, and rectum.
Bacterial Strains and Ciprofloxacin Resistance
All strains belonging to the species E. cloacae  or E. coli
cultured in the microbiology laboratory of the Erasmus Uni-
versity Medical Center Rotterdam (EMCR), having an MIC
for ciprofloxacin >2 mg/mL and isolated from November
1998 to October 1999, were selected from stock cultures. A
general antimicrobial-resistance profile was generated by
the commercial MicroScan Walk-A-Way system (Dade
Behring, Paris, France) according to the manufacturer’s
instructions. On the basis of this analysis, all ciprofloxacin-
resistant strains were identified and included in the study.
The MICs of ciprofloxacin, ceftazidime, gentamicin, tobramy-
cin, amikacin, cotrimoxazole, imipenem, and colistin were
determined by agar dilution testing according to guidelines
of the National Committee for Clinical Laboratory Stan-
dards (NCCLS) (22). Strains were classified as susceptible
(S), intermediate (I), or resistant (R) according to NCCLS
breakpoints. Finally, to define the nature of the gentamicin
resistance, strains were phenotypically analyzed with the
Vitek2 Advanced Expert System (bioMerieux, Lyon, France).
Gram-negative susceptibility cards (ASTN-010) were inocu-
lated with a 0.6 McFarland suspension of the strains
involved. A description of the aminoglycoside resistance
genes is provided. From November 1998 to October 1999,
164 isolates of ciprofloxacin-resistant enterobacteriaceae
were retrieved from 45 patients. A total of 159 isolates were
identified as either E. coli or E. cloacae; the five other iso-
lates could not be identified unambiguously. Overall, 108 of
159 isolates from 33 patients (from 1 to 7 per patient) were
available for further study. Fifty-one appeared to be E. coli
and 57 belonged to the species E. cloacae. Of 33 patients, 6
showed clear evidence of clinically significant infection with
E. coli (n = 5) or E. cloacae (n = 1). The other 27 patients
were colonized with these resistant organisms, but had no
clear symptoms or signs of clinical infection.
DNA Isolation
DNA isolation from individual colonies of cells was per-
formed with the guanidinium-Celite protocol described by
Boom et al. (23). DNA concentration was assessed by agarose
gel electrophoresis of aliquots and staining by ethidium bro-
mide in comparison with known amounts of lambda DNA.
DNA was stored at a concentration of 5 ng/mL in 10 mM tris-
HCl pH 8.0, 0.1 mM EDTA at -20°C.
Amplification and Characterization of Integrons
PCR mapping of integrons can be done on the basis of
their 5' and 3' conserved regions. PCR was carried out in
100-mL volumes, essentially as described by Levesque et al.
(24). The sequences for the 3' and 5' CS primers were
GGCATCCAAGCAGCAAG and AAGCAGACTT-GACCTGA,
respectively. Amplifications included 50 ng of bacterial DNA
and cycling consisted of 35 repetitions of 1 min at 94°C, 1
min at 60°C, and 5 min at 74°C. Amplification products were
analyzed by agarose gel electrophoresis. Besides length
assessment, RFLP was determined for all amplicons. For
these experiments, the endonuclease AluI was used accord-
ing to the manufacturer’s instructions (Boehringer-Man-
nheim, Mannheim, Germany).
Random Amplification of Polymorphic DNA (RAPD)
RAPD was performed for the E. coli strains essentially
as described (25). Primers for amplification were ERIC-1 and
ERIC-2 (26). The PCR protocol consisted of 40 cycles of dena-
turation (1 min at 94°C), annealing (1 min at 25°C) and
chain extension (2 min at 74°C). Reaction products were ana-
lyzed by agarose gel electrophoresis; single differences in
banding patterns among strains led to the definition of novel
genotypes.
Pulsed-Field Gel Electrophoresis (PFGE)
Before PFGE, strains were grown overnight on Brucella
blood agar plates (bioMerieux, Lyon, France). Cells were
embedded in 0.5% low melting point InCert agarose (FMC
Bioproducts, Landgraaf, the Netherlands) buffered in 5 mM
tris-HCl pH 8.0, 50 mM Na2EDTA, 5 mM EGTA. The blocks
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Table 1. Survey of epidemiologic and genetic data for the ciprofloxacin-resistant enterobacteriaceae isolated in the three hematology wards
Patient strain 
no. Material Date of isolation Dept.
Integron tests
PFGE Res. type
Aminoglycoside 
enzymeSize RFLP
Enterobacter cloacae
1-1 fc 12-30-98 A A SL
2-1 bc 10-23-99 C 2,000/2,200 A B CGTASL E
2-2 bc 10-23-99 C A B CGTASL E
3-1 re 07-13-99 A C SL
3-2 re 08-05-99 A C SL
3-3 ur 08-11-99 A C SL
3-4 re 10-04-00 A C SL
4-1 re 06-07-99 A C SL
4-2 re 06-21-99 A C SL
5-1 re 02-01-99 B 2,000 B D CGTSE
5-2 re 02-04-99 B 2,000 B D GTS E
5-3 ur 02-04-99 B 2,000 B D GS BCDE
5-4 re 02-08-99 B 2,000 -- E GTS E
6-1 re 07-05-99 A -- -- C SL
6-2 re 07-26-99 A -- -- C SL
6-3 ur 07-27-99 A -- -- C SL
6-4 -- -- A -- -- C SL
7-1 fc 12-18-98 A 2,000/2,200 A F GSL B
7-2 re 12-21-98 A 2,000/2,200 A G GCTAS B
8-1 re 06-28-99 A C SL E
8-2 ur 06-28-99 A C SL
9-1 fc 01-15-99 A H --
9-2 fc 01-18-99 A H S
9-3 fc 01-21-99 A H S
9-4 fc 01-25-99 A H S
9-5 fc 01-28-99 A H CS
10-1 re 04-19-99 B 2,000 B E GTS E
11-1 re 06-07-99 C 2,000/2,200 A B CGTASL E
11-2 re 06-18-99 C 2,000 B I CGTAL E
11-3 re 06-21-99 C 2,000/2,200 A J CGTASL D
11-4 re 07-05-99 C 2,000/2,200 A B CGTASL
11-5 we 07-11-99 C 2,000/2,200 A B CGTASL
11-6 re 07-12-99 C 2,000/2,200 A B CGTASL
11-7 ur 08-04-99 C 2,000/2,200 A B
12-1 fc 12-26-98 A C SL
12-2 sk 01-15-99 A C SL
12-3 wd 01-15-99 A C CSL
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Table 1. (continued) Survey of epidemiologic and genetic data for the ciprofloxacin-resistant enterobacteriaceae isolated in the three hematology
wards 
Patient strain 
no. Material Date of isolation Dept.
Integron tests
PFGE Res. type
Aminoglycoside 
enzymeSize RFLP
Enterobacter cloacae
12-4 fc 01-18-99 A C SL
13-1 fc 03-08-99 C 2,000/2,200 A B CGTAE
13-2 ur 03-09-99 C 2,000/2,200 A K CGTSE
13-3 fc 03-15-99 C 2,000/2,200 A B CGTSL E
13-4 ur 03-16-99 C 2,000/2,200 A Q CGTASL F
13-5 re 03-22-99 C 2,000/2,200 A J CGTSL E
14-1 ur 08-05-99 A -- --
15-1 re 07-26-99 C 2,000/2,200 A L CGTASL E
15-2 re 08-02-99 C 2,000/2,200 A M CGTASL E
15-3 fc 08–06-99 C 2,000/2,200 A M CGTASL
15-4 re 08-26-99 C 2,000/2,200 A M CGTASL
15-5 re 08-30-99 C 2,000/2,200 A ? CGTASL E
15-6 -- -- C 2,000/2,200 A N CGTASL E
15-7 re 09-03-99 C 2,000/2,200 A M CGTASL E
15-8 re 09-06-99 C 2,000/2,200 A L CGTASL E
15-9 re 09-30-99 C 2,000/2,200 A L CGTASL
16-1 re 06-21-99 A C SL
17-1 re 09-17-99 B 2,000/2,200 A P CGTS E
18-1 bc -- -- 2,000/2,200 A M
Escherichia coli
1-1 bc 12-31-98 A 2,000 - L S
20-1 re 10-07-99 B M
20-2 re 10-11-99 B M
20-3 re 10-18-99 B M
21-1 fc 11-19-98 B 1,000/1,800 C L GTS AB
21-2 fc 11-12-98 B 1,000/1,800 C L GTS
21-3 fc 11-15-98 B 1,000/1,800 C L GTS
21-4 fc 11-17-98 B 1,000/1,800 C L GTS
21-5 fc 11-17-98 B 1,000/1,800 C L GTS AB
22-1 fc 01-04-98 A 2,700 D N TS
22-2 re 01-11-99 A 2,700 D N TS
22-3 re 02-25-99 B 2,700 D N S
22-4 ur 02-25-99 B 2,700 D N TS
22-5 re 04-06-99 B 2,700 D N TS
22-6 re 04-06-99 B 2,700 D N TS
23-1 re 09-04-99 A 1,800 E O GTS AB
23-2 re 09-06-99 A 1,800 E O GTS
23-3 re 09-13-99 A 1,800 E O GTS
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Table 1. (continued) Survey of epidemiologic and genetic data for the ciprofloxacin-resistant enterobacteriaceae isolated in the three hematology
wards 
Patient strain 
no. Material Date of isolation Dept.
Integron tests
PFGE Res. type
Aminoglycoside 
enzymeSize RFLP
Enterobacter cloacae
23-5 ur 10-21-99 A 1,800 E O GTS AB
24-1 re 09-26-99 A 1,500 F A GS ABCD
24-2 re 10-11-99 A 1,500 F A GS
25-1 fc 01-11-99 A J S
25-2 fc 01-13-99 B K S
26-1 re 10-11-99 B 1,500 F I GTS ABCDE
27-1 ur 03-09-00 C G S
27-2 -- -- C G S
27-3 ur 03-10-99 C H S
27-4 -- -- C H S
27-5 ur 03-22-99 C H S
27-6 ur 03-25-99 C C S
28-1 re 02-01-99 C --
28-2 ur 02-01-99 C A
28-3 ur 02-15-99 C 1,500 F A GS BCD
28-4 va 02-27-99 C 1,500 F A GS ABCD
28-5 ur 03-15-99 C 1,500 F A GS
29-1 tr 02-01-99 A 1,500 G A GS ABCD
29-2 tr 02-08-99 A B CG CD
29-3 tr 02-23-99 B 1,500 G A GS
30-1 ur 12-07-99 A 1,000/
1,300/1500
I A GS
30-2 fc 12-10-98 A 2,700 D C S F
30-3 fc 12-10-98 A 1,000/
1,300/1500
I D -
31-1 fc 12-07-98 B 1,500/2,000 G A S F
32-1 re 02-11-99 A 1,800 F A CS
32-2 re 02-22-99 A 1,800 F A CS
32-3 re 03-01-99 A 1,800 F A CS F
32-4 cx 03-23-99 A 1,800 F A S
33-1 bc 11-05-99 C 2,000 J A S
34-1 bc 06-21-99 A E GS AB
35-1 ur 09-23-99 A 1,800 ? F GTS AB
Clinical materials from which the samples were derived were feces (fc), blood (bc), rectal swabs (re), urine (ur), wounds (wd), skin (sk), vaginal swabs (va) or
cervical swabs (cx). All strains were resistant to ciprofloxacin, additional antibiotics tested to determine the antibiogram were ceftazidime (C), gentamicin (G),
tobramycin (T), amikacin (A), cotrimoxazole (S), imipenem (I) and colistin (L). The nature of the aminoglycoside modifying enzymes involved was only tested
for those strains for which a result is mentioned. Enzymes are encoded as follows: A: resistant aminoglycoside acetyl transferase AAC(3)-II; B: resistant
aminoglycoside nucleotidyl transferase ANT(2'); C: heterogeneous aminoglycoside phosphotransferase APH(3') + AAC(3)-I; D: resistant AAC(3)-I; E: AAC(6');
F: resistant APH(3').
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were deproteinated by overnight incubation in the same
buffer containing 1% sodium dodecyl sulfate and 1 mg/mL of
proteinase K (Sigma Chemicals, St. Louis, MO) at 37°C.
After extensive washing, blocks were stored at 4°C. Approxi-
mately 3x5-mm portions of the blocks were incubated in the
presence of 40 units of the restriction endonuclease XbaI
(Boehringer-Mannheim, Mannheim, Germany) in the appro-
priate buffer. Incubation at 37°C continued for 18 hours,
after which the blocks were incorporated in 1% Seakem GTG
agarose slabgels (FMC BioProducts, Rockland, ME). The
restriction fragments were separated at a field strength of 6
V/cm for 20 hours at 14°C. The pulse time linearly increased
from 5 sec to 35 sec during electrophoresis (27). Concatemers
of lambda DNA were used as molecular size markers (Bio-
Rad, Veenendaal, the Netherlands). Gels were stained with
ethidium bromide postelectrophoresis and photographed
(Mitsubishi Copy Processor, Progress Control, Waalwijk, the
Netherlands). DNA fingerprints were inspected visually. Sin-
gle band differences were scored for the definition of sepa-
rate genotypes, which is stricter than the guidelines of
Tenover et al., which were not intended for outbreaks of
infection or colonization monitoring (28).
Statistical Analysis
We used Fisher Exact or chi-square tests for analysis of
the differences in incidence of fluoroquinolone resistance. A
two-tailed test p-value of <0.05 was considered statistically
significant.
Results 
Prevalence of Ciprofloxacin-Resistant Enterobacteriaceae
Our study was prompted by the apparent rise in the
incidence of ciprofloxacin-resistant enterobacteriaceae in the
hematology wards of the EMCR, as well as a fatal case of
ciprofloxacin-resistant E. cloacae septicemia in a neutro-
penic patient with cancer. In the hospital as a whole, the
incidence of ciprofloxacin resistance among isolates of E. coli
and E. cloacae has been relatively stable, increasing slightly
from 1996 to 1999 from 3.5% (65 of 1,879 isolates, one per
patient) and 3.4% (12 [4.7%] of 358) to (111 of 2,367; p = 0.06)
and 4.2% (27 of 549; p = 0.3) per species. Among patients in
the hematology wards, however, the incidence of ciprofloxa-
cin-resistant E. coli increased from <0.5% in 1996 to 20.7%
(21 of 82; p = 0.0004) in 1999. Even more notable, the inci-
dence of ciprofloxacin-resistant E. cloacae rose from <0.5% to
64% (16 of 25; p = 0.01) during the same period. Therefore,
the small increase in the overall incidence of ciprofloxacin
resistance among enterobacteriaceae in the entire hospital
was in part attributable to the rise observed in the hematol-
ogy department. 
Overall Antimicrobial Resistance Patterns in Ciprofloxacin-
Resistant Enterobacteriaceae
Resistance patterns were derived from MIC determina-
tions in ciprofloxacin-resistant isolates from individual
patients (Table 1). For patient 1, both a ciprofloxacin-resis-
tant E. coli and an E. cloacae isolate were detected. Clear dif-
ferences were observed in the proportions of E. coli or E.
cloacae strains resistant to the various antibiotics tested
(Table 2). Apparently, the E. cloacae strains are more often
resistant toward ceftazidime, tobramycin, amikacin, cotri-
moxazole, and, most notably, colistin. No strain was found to
be resistant to imipenem. 
Many of the enterobacters appeared multiresistant. The
most prevalent types of resistance were CGTASL (17 [30%]
of 56) and SL (16 [29%] of 56). The E. coli strains were more
diverse with respect to their antibiograms, with the GTS- (12
[24%] of 50) and GS-types (9 [18%] of 50) the most prevalent
multiresistant isolates. These figures are biased, since multi-
ple isolates were included per patient, but also on an individ-
ual basis the SL type is the most prevalent of the
enterobacter strains, with 7 of 18 patients colonized. For the
E. coli strains, the S type is the most frequently encountered
on a patient-to-patient basis (8 of 27). In most cases, serial
isolates from individual patients shared the same antibio-
gram, but exceptions to this rule were observed. 
In addition to the aminoglycoside MIC determinations,
the aminoglycoside-modifying enzymes involved were
defined by the Vitek2 Advanced Expert System (Table 1).
The aminoglycoside resistance trait of the Enterobacter spp.
is primarily determined by the putative presence of an
AAC(6’) gene (aminoglycoside resistance type E; Table 1).
Incidentally, other combinations are documented. This type
Table 2. Proportions of ciprofloxacin-resistant Enterobacter spp and Escherichia coli  strains resistant to other antibioticsa
Antibiotic
Enterobacter E. coli
S (%) I (%) R (%) S (%) I (%) R (%)
Ceftazidime 24 (47) 0 27 (53) 46 (92) 0 4 (8)
Gentamicin 21(41) 6(12) 24(47) 28(56) 0 22(44)
Tobramycin 23 (45) 0 28 (55) 32 (64) 11 (22) 7 (14)
Amikacin 31 (61) 18 (35) 2 (4) 50 (100) 0 0
Cotrimoxazole 0 0 51 (100) 7 (14) 0 43 (86)
Imipenem 51 (100) 0 0 50 (100) 0 0
Colistin 12 (24) 0 39(76) 48(96) 0 0
aThe figures express the absolute number of susceptible (S), intermediate (I) and resistant (R) strains defined according to the 1999 NCCLS Guidelines [22].
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of resistance always correlated with the presence of an inte-
gron. For the E. coli strains, more heterogeneous aminogly-
coside resistance gene contents were documented.
Aminoglycoside resistance was never recorded in the
absence of an integron.
Genetic Typing of the Enterobacteriaceae
Genetic heterogeneity among the E. cloacae strains was
assessed by PFGE (Figure 1). A relatively large proportion
(approximately 33%) of the E. coli strains appeared to be
reproducibly nontypeable by PFGE. During two independent
experiments, no distinct banding patterns were generated,
and only smears of degraded DNA were seen. Therefore, we
decided to type all strains by using independent RAPD
assays. With this approach, all strains appeared to be type-
able. Moreover, the NotI PFGE data that were available for
the PFGE-typeable subset of the strains were in full agree-
ment with the RAPD data (results not shown). A survey of
all PFGE- or RAPD-based genetic codes is presented in Table
1. E. cloacae  strains were isolated from diverse clinical speci-
mens derived from 18 patients. Sixteen PFGE types were
determined. Among five patients who were colonized or
infected by multiple types, two patients had three types and
one patient was colonized by as many as four different PFGE
genotypes. Several genotypes were encountered in more
than one patient. Types B were isolated from three patients,
and types E-J-M were detected in two patients each. These
patients had not been clustered in time or space, so a com-
mon infectious source may exist that is unrelated to any of
these patients. Type B occurred in 3 of 5 patients housed in
Unit C, indicating that transmission is also a possibility in
the highly restricted wards. Shared strains were also docu-
mented for patients in the high-level isolation, single-person
units with anterooms and separate bathrooms, but could not
be explained on the basis of patient-to-patient contacts. Most
specific genotypes were confined to a single patient, where
they were persistently found. The six patients who carried
type C were admitted to ward A during overlapping time
intervals (Figure 2), indicating that this type is an important
nosocomial pathogen. The strains were derived from a vari-
ety of clinical specimens.
The isolates of E. coli were retrieved from 17 patients,
and 15 different RAPD types were documented. Two
patients were colonized with two strains, and two other
patients with three different strains. One of these patients
was transferred to another unit during his stay in the hema-
tology department. Several RAPD type-strains were found in
more than one patient. Types L and C were encountered
twice, and type A was found in seven patients. For the type A
strain, limited overlap in time and space was documented for
the patients involved (late 1998 to early 1999). Four of them
were in unit A (40% of all patients in that ward during the
screening period were colonized with ciprofloxacin-resistant
strains) (Figure 2). The possibility of a non-patient-associ-
ated environmental source remains, especially because bac-
terial dissemination was not restricted to the A unit, where
physical isolation was less strict and several patients shared
rooms. Putative explanations for spread are carriage by staff
members or contamination of showers or toilets, but neither
potential source was examined systematically during the
study.
Figure 2. Clustering in time of the
pulsed-field gel electrophoresis type
C strains of Enterobacter cloacae and
the RAPD type A strains of Escheri-
chia coli for isolates from the low-
care hematology Unit A. Note that
RAPD type A E. coli strains were
also retrieved from two patients in
another unit (patients 28 and 33).
The dates on which positive cultures
were obtained are indicated by +; the
horizontal bars indicate the periods
during which the patients were in
Unit A.
Figure 1. Pulsed-field gel electrophoresis of XbaI macrorestriction
fragments for the ciprofloxacin-resistant Enterobacter cloacae
strains. Examples of different sets of patient isolates are shown. The
interpretation of these experimental data is given in Table 1. Note
the minor differences, for example, among strains 11-1, 11-2, and 11-
3. Not all fingerprints for the strains analyzed for each of the
patients are presented. The arrows on the left and right indicate the
position of the 250-kbp marker molecule.
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Integron Analysis
Detection of integron sequences was performed with a
straightforward PCR assay. The results of these amplifica-
tions and the molecular sizes of the amplicons are summa-
rized in Table 1. The integrons among the E. cloacae strains
are clearly similar in structure and composition. In 26 (46%)
of 56 strains, two different integrons were detected. In six
additional strains, only the smaller one (2,000 bp) was
detected. When the amplicons were digested with AluI,
homogeneous RFLP patterns were observed, suggesting sim-
ilarity of the two integrons (Figure 3A). The presence of the
integrons correlates with resistance of the strains to gentam-
icin, tobramycin, and amikacin. Among the E. coli strains,
greater diversity of PCR products was detected (Table 1)
(Figure 3B). At least seven different-sized PCR products
were visualized. Moreover, similar-sized integron amplicons
can give rise to different RFLP patterns, indicating even
more extensive heterogeneity. Thirty-five (70%) of 50 strains
had one or more integrons. The association between integron
presence and gentamicin resistance is still present, but is
not as strong as for the E. cloacae  strains. 
Discussion
We describe a study in a hematology department with
patients housed in three clinical units in two buildings. As
the antibiotic policy, especially the use of ciprofloxacin for
selective decontamination, is identical throughout the
department, the occurrence and means of spread of ciproflox-
acin-resistant gram-negative bacilli can be measured
against patient-related or environmental features. This
study was initiated after we observed that the overall inci-
dence of bacterial ciprofloxacin resistance in the hematology
department had substantially exceeded that of the hospital
as a whole. Moreover, these resistant organisms resulted in
clinical infections in a significant proportion of the patients.
Of the patients that we could track, 6 (18%) of 33 at any
given time had bacteremia with a ciprofloxacin-resistant
microorganism. Our study does not allow definite conclu-
sions to be drawn on the relationship between the increased
incidence of resistance on the one hand and bacterial genetic
variability on the other. This would require analysis of sus-
ceptible strains as well, both from the hematology wards and
other wards of the same hospital. However, our observations
do provide insight into the molecular epidemiology of cipro-
floxacin-resistant organisms and, separately, gentamicin
resistance encoding integrons in the hematology depart-
ment.
Outbreaks Caused by Ciprofloxacin-Resistant 
Microorganisms
PFGE has been used to study the dissemination of cipro-
floxacin-susceptible Enterobacter strains in detail in various
clinical settings (14,27,29-31). As such, the method is well
accepted and has proven epidemiologic efficacy. We show dis-
semination of a PFGE type C E. cloacae strain in Unit A.
This finding emphasized the need for adequate implementa-
tion of robust barriers in nursing hematology patients. Hand
disinfection, both for patients and personnel, and the use of
gloves and gowns by staff members are indispensable. After
patients were specifically instructed on how to wash their
hands after using the bathroom, the incidence of ciprofloxa-
cin-resistant strains decreased (data not shown). However,
in light of the overlapping genotypes, all clinical personnel
involved should be aware of the potential for resistant bacte-
ria to spread from patient to patient, within the environ-
ment, or among persons acting as potential vectors. 
On two separate occasions, PFGE failed to type 33% of
all ciprofloxacin-resistant E. coli strains. Therefore, we
turned to random amplification of polymorphic DNA (RAPD)
analysis, which has been used successfully to elucidate epi-
demic spread of E. coli (25,26) and appeared to be useful
here as well. E. coli strains were 100% typeable with this lat-
ter technique. A possible nosocomial outbreak was assessed
for RAPD type A. This type also occurred in the multiperson
rooms in Unit A. The level of barriers (e.g., negative airflow,
use of gloves and gowns) seems to be associated with the
likelihood of an outbreak. A recent study performed in
another Dutch university hospital identified 21 hematologic
cancer patients colonized (79%) or infected (21%) with a
ciprofloxacin-resistant E. coli strain over a 5-year period
(32). An increase in incidence was noted over the years,
whereas limited RAPD analyses suggested that nosocomial
transmission had occurred. Overall, the observations from
the two Dutch university hospitals suggest that the use of
ciprofloxacin may predispose to outbreaks due to ciprofloxa-
cin-resistant E. coli strains.
Integron Epidemiology
An integron is a genetic element that possesses a site at
which cassettes of DNA can be integrated by site-specific
recombination. The integron encodes an integrase enzyme
that mediates the recombination events (18,19). Integrons
are not independently mobile but may be found as part of
transposons or plasmids, and the genes that they contain
may not always be expressed with equal effectiveness (33).
Such features may favor or limit the successful spread of
integrons and may also provide a likely explanation for their
ubiquity among gram-negative bacilli (34,35). A pan-Euro-
Figure 3. Amplification fragment length polymorphism analysis
analysis of the Enterobacter cloacae and Escherichia coli integron
amplicons. A. AluI restriction fragment length polymorphism
(RFLP) patterns for the integrons amplified from the E. cloacae
strains. Patients and strains are identified above the lanes. Lanes
marked M contain molecular length markers; the 200-bp fragment
is identified on the left. Two different patterns are identified: only
strains 11-2, 5-1, 5-2, 5-3, and 10-1 show a slightly different mixture
of restriction fragments (2 are missing). B. AluI RFLP patterns for
the integrons amplified from the E. coli strains. Patients and strains
are identified above the lanes; lanes marked M contain molecular
length markers, with the 200-bp fragment is identified on the left.
Note the clear difference in complexity in comparison with the
homogeneous patterns shown in figure 3A.
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pean study recently revealed that >40% of all gram-negative
clinical isolates harbor integrons and that the presence of
integrons is associated with increased frequency of multire-
sistance and distinct resistance against aminoglycosides,
quinolones, and beta-lactam compounds (36). In addition,
the same authors suggested in a follow-up study that the
conserved nature of the integrons that were identified could
be an indication of the spread of entire integrons rather than
the cassettes only (37). Integrons are assumed to play an
important role in the dissemination of antimicrobial resis-
tance (38). The contribution of integron cassettes to the prev-
alence of transferable aminoglycoside resistance has been
demonstrated in a French hospital (39). 
We have decribed the frequent occurrence of integron-
encoded gentamicin resistance among nosocomial isolates of
ciprofloxacin-resistant E. cloacae strains. Among the E. cloa-
cae strains, two different integron types were encountered
against a diverse background of chromosomes. This could be
indicative of intraspecies dissemination of these particular
elements, either as a whole or as the cassette content only,
suggesting a strong species barrier. In case of the E. coli iso-
lates, the integron types had greater diversity. Furthermore,
the E. cloacae integron types were primarily confined to cer-
tain hematology units. Surprisingly, this suggests that a spe-
cies barrier exists, prohibiting integron transfer between
Enterobacter sp. and E. coli. In contrast to this observation,
and substantiated by the fact that indiscriminate integrons
occur in various bacterial strain types, exchange of integrons
between strains of a single species seems to be effective. Fur-
thermore, some integron types seem to be confined to a cer-
tain patient unit. In addition, our data indicate that in
clinics where relatively large amounts of antibiotics are pre-
scribed, resistance determinants may accumulate, especially
in strains that show patient-to-patient transmission.
In conclusion, we describe differences in the nosocomial
epidemiology of ciprofloxacin-resistant enterobacteriaceae.
Besides variation in integron content, different species-spe-
cific integrons appear to circulate within the shared clinical
environment. The observed differences between the spread
of strains compared with antimicrobial resistance traits
encoded by integrons merit additional investigations. We
hypothesize that the use of various antibiotics, whether or
not in combination, may have acted as a selective force in the
emergence and dissemination of resistant microorganisms or
their resistance-associated traits.
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